Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma-Reference-Cited by-同舟云学术

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma

Published:2019-03-19 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Khair Duaa O.,Bax Heather J.,Mele Silvia,Crescioli Silvia,Pellizzari Giulia,Khiabany Atousa,Nakamura Mano,Harris Robert J.,French Elise,Hoffmann Ricarda M.,Williams Iwan P.,Cheung Anthony,Thair Benjamin,Beales Charlie T.,Touizer Emma,Signell Adrian W.,Tasnova Nahrin L.,Spicer James F.,Josephs Debra H.,Geh Jenny L.,MacKenzie Ross Alastair,Healy Ciaran,Papa Sophie,Lacy Katie E.,Karagiannis Sophia N.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference144 articles.

1. Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer;James;BMC Cancer.,2017

2. CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma;Dudley;Clin Cancer Res.,2010

3. Cytokines in cancer pathogenesis and cancer therapy;Dranoff;Nat Rev Cancer.,2004

4. Interferon alpha/beta enhances the cytotoxic response of MEK inhibition in melanoma;Litvin;Mol Cell.,2015

5. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies;Atkins;Clin Cancer Res.,1997

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma;Immunotherapy;2024-03

2. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma;Oncotarget;2024-02-05

3. Integrated germline and somatic features reveal divergent immune pathways driving ICB response;2024-01-15

4. Multifunctional nanoparticle-mediated combining therapy for human diseases;Signal Transduction and Targeted Therapy;2024-01-01

5. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis;Annals of Oncology;2023-12